Suat Özlük
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Suat Özlük has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Ayşe Özdemir
Affiliation Department of Histology and Embryology, University of Health Sciences Gülhane Faculty of Medicine, Ankara, Türkiye
1 shared publication - Ayşe Özkaçmaz
Van Yüzüncü Yıl University School of Medicine
1 shared publication - Cenk Aypak
University of Health Sciences, Department of Family Medicine, Ankara Etlik City Hospital
1 shared publication - Mehmet Parlak
VAN YÜZÜNCÜ YIL ÜNİVERSİTESİ, TIP FAKÜLTESİ
1 shared publication - Nazik Doğramaci Köprülü
KAHRAMANMARAŞ NECİP FAZIL ŞEHİR HASTANESİ
1 shared publication - Yasemin Bayram
Department of Microbiology, Faculty of Medicine, Yüzüncü Yıl University , Van 65080 , Turkey
1 shared publication
Latest Publications
- Open Access
- 1 June 2023
- Published by University of Rzeszow in European Journal of Clinical and Experimental Medicine
- Vol. 21 (2) , 283-288
Antiviral drug resistance rates among patients with chronic hepatitis B infection
Introduction and aim. Chronic hepatitis B infection (CHB) affects millions of people around the world. Many clinicians find it challenging to choose therapeutic agents due to the mutations that occur in the hepatitis B virus (HBV) that cause drug resistance. Thus, the aim of this study was to determine the HBV resistance rates against the currently recommended first-line therapies in the region of our country where HBV prevalence is high. Material and methods. A total of 96 patients (56 men and 40 women) with HBV infection were enrolled in the study. The serum samples collected from those were analyzed with real-time polymerase chain reaction analysis followed by pyrosequencing (PyroStar HBV Drug Resistance Test, Altona Diagnostics, Germany) for drug resistance mutations associated with lamivudine, adefovir, telbivudine, entecavir, and tenofovir. Results. HBV drug-resistance mutations were investigated in 80 treatment-naïve and 16 treatment-experienced patients (6 entecavir, 4 PEGylated-interferon, 4 tenofovir, 2 lamivudine). None of the HBV-DNA samples had mutations cause to drug resistance were detected in any codons regions that were analyzed. Conclusion. Antiviral resistance poses serious obstacles for clinicians in the treatment of CHB. Determining whether antiviral resistance exists in HBV is critical to choose the appropriate treatment agent.
- 1 June 2023
- Published by University of Rzeszow in European Journal of Clinical and Experimental Medicine
- Vol. 21 (2) , 283-288
Open AccessAntiviral drug resistance rates among patients with chronic hepatitis B infection
Introduction and aim. Chronic hepatitis B infection (CHB) affects millions of people around the world. Many clinicians find it challenging to choose therapeutic agents due to the mutations that occur in the hepatitis B virus (HBV) that cause drug resistance. Thus, the aim of this study was to determine the HBV resistance rates against the currently recommended first-line therapies in the region of our country where HBV prevalence is high. Material and methods. A total of 96 patients (56 men and 40 women) with HBV infection were enrolled in the study. The serum samples collected from those were analyzed with real-time polymerase chain reaction analysis followed by pyrosequencing (PyroStar HBV Drug Resistance Test, Altona Diagnostics, Germany) for drug resistance mutations associated with lamivudine, adefovir, telbivudine, entecavir, and tenofovir. Results. HBV drug-resistance mutations were investigated in 80 treatment-naïve and 16 treatment-experienced patients (6 entecavir, 4 PEGylated-interferon, 4 tenofovir, 2 lamivudine). None of the HBV-DNA samples had mutations cause to drug resistance were detected in any codons regions that were analyzed. Conclusion. Antiviral resistance poses serious obstacles for clinicians in the treatment of CHB. Determining whether antiviral resistance exists in HBV is critical to choose the appropriate treatment agent.
- 11 March 2021
- Published by Konuralp Medical Journal in Konuralp Tip Dergisi
- Vol. 13 (1) , 18-23
Relationship of ABO Blood Groups to SARS-COV-2 Infection Causing COVID-19 Disease
Objective: We aimed to investigate whether there is a predisposition to COVID-19 with ABO and Rh blood group systems. Methods: The clinical data of 455 patients with COVID-19 seen between April 17, 2020, and June 30, 2020, at the Necip Fazıl City Hospital were retrospectively analyzed studied. The differences in the ABO blood group distribution between COVID-19 patients and the control group (7844 cases) were analyzed. Results: The percentage of patients with type O blood in the COVID-19 group was significantly lower than that in the control group (29.7% vs. 35.6%, p = 0.009). The percentage of patients with type A and B blood in the COVID-19 set was higher than in the control group however, there were no significant differences, respectively (44.4% vs. 40.8%, 19.3% vs.16.6%, p = 0.134, p=0.123). Patients with blood group O had a lower risk of COVID-19 than A, B blood group patients (respectively; OR = 0.732, OR=0.594, p = 0.023, p=0.001). The risk of COVID-19 was higher for patients with blood groups A and B than with a blood group 0 (OR = 1.365, OR= 1.684, p = 0.023, p=0.001). The Rh blood group phenotype was not statistically significant in determining a patient’s vulnerability. Conclusion: The results of the present study suggest that while the blood group 0 had a low risk and decreased risk for infection with SARS-CoV-2, whereas blood group A and B were associated related with an increased risk, indicating that certain specific ABO blood groups were connected correlated with SARS-CoV-2 susceptibility.
- 11 March 2021
- Published by Konuralp Medical Journal in Konuralp Tip Dergisi
- Vol. 13 (1) , 18-23
Relationship of ABO Blood Groups to SARS-COV-2 Infection Causing COVID-19 Disease
Objective: We aimed to investigate whether there is a predisposition to COVID-19 with ABO and Rh blood group systems. Methods: The clinical data of 455 patients with COVID-19 seen between April 17, 2020, and June 30, 2020, at the Necip Fazıl City Hospital were retrospectively analyzed studied. The differences in the ABO blood group distribution between COVID-19 patients and the control group (7844 cases) were analyzed. Results: The percentage of patients with type O blood in the COVID-19 group was significantly lower than that in the control group (29.7% vs. 35.6%, p = 0.009). The percentage of patients with type A and B blood in the COVID-19 set was higher than in the control group however, there were no significant differences, respectively (44.4% vs. 40.8%, 19.3% vs.16.6%, p = 0.134, p=0.123). Patients with blood group O had a lower risk of COVID-19 than A, B blood group patients (respectively; OR = 0.732, OR=0.594, p = 0.023, p=0.001). The risk of COVID-19 was higher for patients with blood groups A and B than with a blood group 0 (OR = 1.365, OR= 1.684, p = 0.023, p=0.001). The Rh blood group phenotype was not statistically significant in determining a patient’s vulnerability. Conclusion: The results of the present study suggest that while the blood group 0 had a low risk and decreased risk for infection with SARS-CoV-2, whereas blood group A and B were associated related with an increased risk, indicating that certain specific ABO blood groups were connected correlated with SARS-CoV-2 susceptibility.